From Yahoo Finance: 2025-05-13 07:21:00

US-based Abeona Therapeutics sold its priority review voucher for $155m after gaining FDA approval for gene therapy Zevaskyn, treating the rare disease RDEB. Stock soared 16.8% post-sale announcement. Abeona plans to use funds for over two years of expenses without external capital. Zevaskyn’s commercial launch is set for Q3 2025 at $3.1m per dose.

The voucher sale trend continues with Zevra and PTC Therapeutics selling for $150m each. Highest sale at $350m in 2015. Recent deals show vouchers rising in value, challenging the stable $100m average. Uncertain US funding landscape amplifies voucher importance for biotechs developing rare disease treatments.

Rare disease development faces uncertainty as Trump administration layoffs impact health agencies. Failure to renew priority review voucher programme for paediatric rare diseases adds to the risk. Future rare disease pipelines could suffer due to shifting political priorities. Abeona’s voucher sale secures cash runway for the company’s operations.



Read more at Yahoo Finance: Abeona secures cash runway with $155m priority review voucher sale